A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines
The year 2018 was a breakthrough period for RNA therapeutics as the first RNA therapy received approval from the FDA. In the wake of the COVID-19 pandemic, RNA vaccines have witnessed immense progress and acceptance globally. These events have contributed massively to growth across the RNA therapeutics market.
Currently, several RNA therapeutics are in different stages of development, including mRNA, tRNA, siRNA, and RNAi therapies, but mostly concentrated in the early pre-clinical and clinical stages. The popularity of RNA therapeutics is demanding the need to establish efficient delivery systems that can overcome current challenges, such as early degradation of RNA therapeutic molecules, toxicity, and non-target specificity.
This RNA Delivery Technologies, 2021 Frost Radar covers companies that are developing robust delivery systems for the rapidly growing RNA therapies and adopting the latest advances in nanoscience and chemically modified delivery systems. These delivery systems are critical to achieving the final results in the efficiency of RNA therapeutics.
The publisher identifies key companies that are developing innovative RNA delivery technologies and excelling in the field. Although the newer delivery systems are mostly in pre-clinical stages, the potential of newer delivery systems based on exosomes, chemically modified systems, and polymer-based systems are highly promising.
The publisher independently plotted the top companies in this Frost Radar. Our analysis reveals the market positioning of each company using its Growth and Innovation scores as highlighted in the Frost Radar methodology. The document presents competitive profiles of each of the companies based on their strengths, opportunities, and market positioning. We discuss strategic market imperatives and the competitive environment that vendors operate in as well as make recommendations for each provider to spur growth.
Table of Contents
1. Strategic Imperative and Growth Environment
- Strategic Imperative
- Growth Environment
2. Frost Radar RNA Delivery Technologies
3. Companies to Action:
- Alnylam Pharmaceuticals, US
- Arcturus Therapeutics, US
- Arrowhead Pharmaceuticals, US
- Capricor Therapeutics, US
- Codiak Bioscience, US
- Dicerna Pharmaceuticals, US
- DTx Pharmaceuticals, US
- Ethris, Germany
- Evox Therapeutics, US
- Ionis Pharmaceuticals, US
- Precision NanoSystems, Canada
- Recode Therapeutics, US
- siRNAgen Therapeutics, South Korea
- Translate Bio, US
- Vesigen Therapeutics, US
4. Strategic Insights
5. Next Steps: Leveraging the Frost Radar to Empower Key Stakeholders
- Significance of Being on the Frost Radar
- Frost Radar Empowers the CEO’s Growth Team
- Frost Radar Empowers Investors
- Frost Radar Empowers Customers
- Frost Radar Empowers the Board of Directors
6. Frost Radar Analytics
- Frost Radar: Benchmarking Future Growth Potential
- Legal Disclaimer
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals, US
- Arcturus Therapeutics, US
- Arrowhead Pharmaceuticals, US
- Capricor Therapeutics, US
- Codiak Bioscience, US
- Dicerna Pharmaceuticals, US
- DTx Pharmaceuticals, US
- Ethris, Germany
- Evox Therapeutics, US
- Ionis Pharmaceuticals, US
- Precision NanoSystems, Canada
- Recode Therapeutics, US
- siRNAgen Therapeutics, South Korea
- Translate Bio, US
- Vesigen Therapeutics, US
